Bacil Pharma Board Approves Rights Issue Worth up to 50 Crore

Fund Raising View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹38.36

prior close

₹39.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-1.0% vs market

Pharmaceuticals peers, median of 167sector+0.4%+0.0% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.9

10m

-1.9

15m

-1.9

30m

-2.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+1.4-1.0+0.4+0.0

Next day

-2.2+1.5-3.7+0.8-3.0

-2.2+0.5-2.7+0.5-2.7

-3.9+1.1-5.0+0.6-4.5

-3.8+0.7-4.5+0.5-4.3

-4.8-0.4-4.4-0.7-4.2

-14.3+0.5-14.8+0.3-14.6

15d

-43.0+0.1-43.1-1.8-41.3

-58.1+3.5-61.6-0.6-57.5

-51.6+5.8-57.4+2.4-54.0

-36.3+2.4-38.6-1.5-34.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma board approved a Rights Issue of equity shares worth up to ₹50 Crore. Authorised share capital will rise by ₹45 Crore to ₹65 Crore total. Two Independent Directors resigned. A Rights Issue Committee has been formed and intermediaries (Purva Sharegistry, Axis Bank, Acuite Ratings) appointed. Issue price, entitlement ratio, and record date are yet to be decided.

Likely market impact

Rights Issue may dilute existing shareholders. Use of funds is not disclosed, so watch for further details on purpose and pricing.